Home / Stocks / Viyash Scientific Limited
VIYASH

Viyash Scientific Limited Share Price

Live price, chart and which mutual funds hold this stock

…

as of —

₹—

Change

—

Day Open

₹—

Day High

₹—

Day Low

₹—

NSE Close — 19 Nov 2026

₹235.84

Change

+0.23 (0.1%)

Open

₹236.55

Prev. Close

₹235.61

Day High

₹238.9

Day Low

₹235.1

Volume Analysis

Traded

1,023,824

Delivered

573,686

Delivery %

56.03%

End-of-day NSE price via the official Bhavcopy — updated once daily after market close, not a live tick.

Strengths, Weaknesses, Opportunities & Threats

Strengths (0)

No signal for this stock

Weaknesses (2)

  • •Low return on equity (7.39%)
  • •Promoter holding is falling

Opportunities (1)

  • •Strong 3-year revenue growth (34.0%)

Threats (1)

  • •FII holding has been falling

Rule-based signals from the fundamentals below — not investment advice.

Pivot Levels

Type R3 R2 R1 Pivot S1 S2 S3
Classic ₹241.92 ₹240.41 ₹238.12 ₹236.61 ₹234.32 ₹232.81 ₹230.52
Fibonacci ₹240.41 ₹238.96 ₹238.06 ₹236.61 ₹235.16 ₹234.26 ₹232.81
Camarilla ₹236.89 ₹236.54 ₹236.19 ₹236.61 ₹235.49 ₹235.14 ₹234.8

Support/resistance levels for today, calculated from the previous trading day's high/low/close.

Absolute Returns

YTD

—

1 Week

-6.5%

1 Month

+10.42%

3 Months

-14.54%

6 Months

-4.15%

1 Year

—

2Y/3Y/5Y not shown yet — price history tracking only goes back to mid-2025 so far.

Stock Vitals

Computed from the latest available annual financials.

Graham Number

₹80.93

Current price is above the Graham Number — Benjamin Graham's estimate of fair value based on earnings and book value.

DuPont ROE Breakdown

8.15%

Net margin 7.51% × asset turnover 0.67x × equity multiplier 1.62x

Company Overview

Sector

Healthcare

Market Cap

₹11,285 Cr

P/E (TTM)

46.6

ROE

7.39%

Book Value

₹71.7

Face Value

₹2.0

Source: Screener.in (Consolidated figures) — data as of 16 Nov 2026. Not investment advice.

TopFund Analysis

Viyash Scientific Limited lands in the middle of the pack on TopFund's composite fundamentals check within the Healthcare sector, at 59/100. The strongest factor is Financial Strength (100/100), while Valuation (25/100) is the weakest area to weigh before deciding. Notably: Low return on equity (7.39%); promoter holding is falling. FII holding has been falling.

TopFund Score — Fundamentals Quality

59/100 — Average

Data confidence: 79/100 (Moderate Confidence) — based on how complete and how fresh the underlying data is.

As of 19 Nov 2026 · How we calculate this →

Financial Strength

100

Growth

68

Valuation

25

Cash Flow

59

Corporate Governance

43

Momentum

64

Institutional Ownership

38

Business Quality

59

Risk & Volatility

47

Liquidity

81

From Screener.in

  • +Company is expected to give good quarter
  • −Stock is trading at 3.56 times its book value
  • −Though the company is reporting repeated profits, it is not paying out dividend
  • −Promoter holding has decreased over last quarter: -12.1%
  • −Company has a low return on equity of 3.80% over last 3 years.

Not investment advice — an automated read of public fundamentals data, for research context only.

Corporate Actions

Source: BSE regulatory filings, via Screener.in.

Quarterly Results

Last several quarters

  Sep 2023 Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Sales + 346 329 361 390 369 774 402 792 850 858 920 946 988
Expenses + 331 307 329 348 330 674 355 673 677 683 736 768 823
Operating Profit 15 22 32 42 39 100 46 119 173 176 184 178 165
OPM % 4.4% 7.0% 9.0% 11.0% 11.0% 13.0% 12.0% 15.0% 20.0% 20.0% 20.0% 19.0% 17.0%
Other Income + 10 7 -1 3 0 4 1 6 6 -27 16 8 12
Interest 13 13 12 16 14 21 15 20 18 17 15 13 14
Depreciation 15 15 16 16 17 58 16 56 59 59 60 62 45
Profit before tax -3 1 3 12 8 24 16 48 102 73 125 112 118
Tax % 123.0% -617.0% 52.0% 24.0% 20.0% -71.0% 36.0% 24.0% 29.0% 34.0% 47.0% 29.0% 28.0%
Net Profit + -7 11 1 9 6 42 10 37 73 49 66 79 85
EPS in Rs 0 0 0 0 0 2 0 1 2 1 1 2 2
Raw PDF — — — — — — — — — — — — —
YoY Sales growth 2 -12 -1 17 7 135 11 103 131 11 129 20 16

Source: Screener.in — figures in ₹ Crores unless marked %.

Profit & Loss (Yearly)

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM
Sales + 443 606 684 848 1,039 1,179 1,362 1,413 1,421 1,370 3,007 3,420 3,713
Expenses + 425 550 641 765 914 1,009 1,150 1,303 1,409 1,308 2,620 2,768 3,009
Operating Profit 18 56 43 83 125 170 212 109 12 61 387 653 703
OPM % 4.2% 9.0% 6.0% 10.0% 12.0% 14.0% 16.0% 8.0% 0.8% 4.5% 13.0% 19.0% 19.0%
Other Income + 48 14 9 436 9 10 0 11 -58 -6 -49 -1 9
Interest 43 38 28 33 33 36 24 16 36 48 86 69 57
Depreciation 32 46 40 41 42 51 51 52 56 62 239 234 226
Profit before tax -8 -14 -17 444 59 94 137 53 -138 -55 13 349 428
Tax % 40.0% 19.0% -3.0% 3.0% 3.0% 13.0% 24.0% 15.0% -11.0% -46.0% -20.0% 36.0% —
Net Profit + -12 -16 -16 431 57 82 104 45 -122 -30 16 225 279
EPS in Rs -1 -1 -1 17 2 3 4 2 -5 -1 1 4 5
Dividend Payout % 0.0% 0.0% 0.0% 1.0% 10.0% 0.0% 13.0% 0.0% 0.0% 0.0% 0.0% 0.0% —
Sales growth 12 37 13 24 23 13 15 4 1 -4 120 14 32

Source: Screener.in — figures in ₹ Crores unless marked %.

Balance Sheet

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Sep 2026
Reserves 61 898 928 599 657 637 678 642 649 607 2,382 2,824 3,076
Borrowings + 473 312 416 305 325 343 277 365 444 488 654 490 584
Other Liabilities + 343 265 503 380 346 424 381 378 374 389 1,042 1,195 1,382
Total Liabilities 908 1,523 1,896 1,332 1,378 1,454 1,386 1,435 1,517 1,534 4,128 4,596 5,131
Fixed Assets + 474 586 684 476 498 577 536 564 605 592 2,103 2,103 2,108
CWIP 39 24 33 18 23 13 31 12 55 16 43 70 42
Investments 59 428 428 239 180 171 83 38 0 4 0 0 0
Other Assets + 336 485 751 599 677 693 737 821 856 922 1,981 2,422 2,981
Total Assets 908 1,523 1,896 1,332 1,378 1,454 1,386 1,435 1,517 1,534 4,128 4,596 5,131
Equity Capital 30 48 49 49 49 50 50 50 50 50 50 87 88

Source: Screener.in — figures in ₹ Crores unless marked %.

Cash Flow

  Mar 2015 Mar 2016 Mar 2017 Mar 2018 Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026
Cash from Operating Activity + -24 0 -7 45 116 115 115 31 17 31 345 323
Cash from Investing Activity + -157 -310 -116 7 -68 -72 10 -94 -65 -6 -448 -84
Cash from Financing Activity + 179 309 147 -57 -20 -43 -139 67 32 -1 87 -123
Net Cash Flow -1 -2 24 -5 28 0 -14 4 -16 23 -16 115
Free Cash Flow -137 -63 -82 0 92 75 70 -1 -58 19 258 225
CFO/EBITDA Share of operating profit converting into cash: CFO (before tax) / Operating Profit -143 -3 5 65 92 75 75 52 263 73 102 59

Source: Screener.in — figures in ₹ Crores unless marked %.

Shareholding Pattern

Quarter-by-quarter — Promoters, FII, DII & public holding trend

Promoter holding: 52.79% → 49.24%
  Dec 2023 Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sep 2026
Others 0.17% 0.17% 0.17% 0.17% 0.16% 0.16% 0.16% 0.16% 0.09% 0.09% 0.09% 0.09%
Public 33.69% 33.29% 33.3% 30.63% 29.12% 28.36% 28.1% 28.69% 27.97% 27.67% 30.34% 39.76%
Promoters 52.79% 52.79% 52.78% 52.76% 52.61% 52.61% 52.61% 52.33% 61.41% 61.31% 61.31% 49.24%
FII 6.12% 6.16% 5.69% 6.45% 6.1% 6.05% 6.15% 5.9% 3.16% 2.94% 4.5% 2.6%
DII 7.23% 7.59% 8.06% 9.99% 12.01% 12.82% 12.98% 12.91% 7.36% 7.98% 3.76% 8.3%

Source: Screener.in — quarterly shareholding disclosures.

Peers Comparison

Healthcare — ranked by market cap

Company Market Cap (Cr) P/E P/B ROE
Viyash Scientific Limited (this stock) 11,285 46.6 3.56 7.39%
Akums Drugs And Pharma L 11,279 29.9 3.22 8.45%
Park Medi World Limited 11,039 43.1 5.12 16.8%
Metropolis Healthcare Ltd 11,711 50.7 7.13 13.6%
Concord Biotech Limited 12,146 42.6 5.86 12.9%
Symbiotec Pharmalab Ltd 10,354 70.0 7.6 11.7%
Yatharth Hosp & Tra C S L 10,222 53.6 5.44 10.2%

Which Mutual Funds Hold Viyash Scientific Limited?

Frequently Asked Questions about Viyash Scientific Limited

Community Sentiment

What are other investors saying about Viyash Scientific Limited?

No votes yet — be the first to share your view.

Sign in to vote

Discussion

User-generated content — not investment advice, and not verified or endorsed by TopFund.

Sign in to join the discussion

No comments yet — start the discussion.